Skyhook Bio provides an AI‑driven platform that automates the design, synthesis, and functional screening of programmable biomolecule libraries. By exploring large combinatorial sequence spaces and linking experimental data to design parameters, it enables biotech and pharma companies to generate and evaluate diverse therapeutic candidates at scale and speed.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional therapeutic discovery relies on limited biological design spaces and slow, manual processes for designing, synthesizing, and testing biomolecules, which hampers the speed and diversity of candidate generation.
Solution
Skyhook Bio offers an AI‑guided platform that automates the design, synthesis, and functional screening of programmable biomolecule libraries. By leveraging advanced machine learning, the system explores vast, previously inaccessible regions of biological sequence space. The platform rapidly generates diverse candidate molecules and evaluates their activity in high‑throughput assays, accelerating the identification of novel therapeutic leads. This integrated workflow enables biotech and pharmaceutical companies to discover differentiated therapeutics at a scale and speed unattainable with conventional methods.
Target Audience
Primary customers are biotech and pharmaceutical organizations seeking to accelerate early‑stage therapeutic discovery and expand their pipeline of novel biologics.
Features
- AI-driven design algorithms that predict functional biomolecule sequences across large combinatorial spaces
- Automated high‑throughput synthesis pipelines for rapid production of diverse library members
- Integrated functional screening assays that assess activity, specificity, and other key properties in parallel
- End‑to‑end data management linking design parameters to experimental outcomes for iterative optimization
- Scalable cloud infrastructure supporting large‑scale library generation and analysis